University of Ioannina
Σχεδιασμός, σύνθεση και βιολογική δράση φαινυλαμινοπυριμιδινών - αναλόγων του φαρμάκου Glivec – ως δραστικών και εκλεκτικών αναστολέων πρωτεϊνικών κινασών
Abstract
dc:descriptionProtein kinases are enzymes that modify other proteins by chemically adding phosphate groups to them and therefore playing a special role in nearly every aspect of cell biology. In the search for low-molecular weight therapeutic agents to treat cancers and other diseases, protein kinases have become attractive targets.Glivec (Imatinib), a clinically important ATP analogue inhibitor that targets the tyrosine kinase domain of the intracellular Abl-Bcr, has revolutionized the treatment of chronic myeloid leukaemia, which is caused by the oncogene Bcr–Abl. As a leading kinase inhibitor, glivec (imatinib) also provides an excellent model system to investigate how changes in drug design impact biological activity.In the present PhD thesis we describe the design, synthesis, and biological evaluation of a new series of phenylaminopyrimidines, structurally related to imatinib, which have in some cases greater activity and selectivity against several protein kinases (Abl-Bcr, KIT, FMS, CDK2/A, B-Raf, PDGFR etc) due to alterations of the phenyl, pyridine and N-methylpiperazine rings: a) lack of the N-methylpiperazine group, b) repositioning of nitrogen in its pyridyl moiety, 2- or 4-position, at the 4-position of the pyrimidine, c) repositioning of the methyl group, d) repositioning of the amide function at the phenyl ring and the incorporation of different groups at the final phenyl ring.The new compounds provide a platform for further drug development against the therapeutically important receptor family PDGF, and they also provide insight into alternative ways of engineering drugs with altered biological activity.Another objective of the present PhD thesis was to provide an improved process for the preparation of the imatinib analogues, overcoming the difficulties of the synthetic process described in patents of the Novartis Company. By our synthetic method the inhibitors were isolated much easier and also obtained in higher yields compared to the Novartis synthetic method. All the 48 new inhibitors described herein were fully characterized by IR, 1H NMR, 13C NMR spectroscopy, as well as by high resolution mass spectrometry.
Degree
thesis:*- Grantor dc:publisher
- University of Ioannina
- Year dc:date
- 2012
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Kinigopoulou, Maria
- Κυνηγοπούλου, Μαρία
Subjects
dc:subject × 20- Πρωτεϊνικές κινάσες
- Εκλεκτικοί αναστολείς κινασών
- Χρόνια μυελογενής λευχαιμία
- Φαρμακευτικό παρασκεύασμα Glivec ή Imatinib
- Φαρμακευτικά σκευάσματα έναντι διάφορων τύπου καρκίνου
- ABL-BCR πρωτεϊνική κινάση
- Σύνθεση φαινυλοαμινο-πυριμιδίνης
- Αναγωγή νιτροομάδας σε αμινομάδα
- Protein kinases
- ATP analogue inhibitor
- Treatment of chronic myeloid leukaemia
- Oncogene Bcr–Abl
- Glivec (Imatinib)
- Synthesis of phenylaminopyrimidines
- Activity and selectivity against tyrosine protein kinases
- Therapeutic agents to treat cancers
- Φυσικές Επιστήμες
- Χημεία
- Natural Sciences
- Chemical Sciences
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/29308